Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib

被引：10

作者：

Jain, Preetesh ^{[1
]}

Kanagal-Shamanna, Rashmi ^{[2
]}

Zhang, Shaojun ^{[3
]}

OK, Chi Young ^{[2
]}

Navsaria, Lucy ^{[1
]}

Nastoupil, Loretta ^{[1
]}

Lee, Hun Ju ^{[1
]}

Tang, Guilin ^{[2
]}

Yin, C. Cameron ^{[2
]}

Badillo, Maria ^{[1
]}

Nair, Ranjit ^{[1
]}

Li, Shaoying ^{[2
]}

Patel, Keyur M. ^{[2
]}

Flowers, Christopher ^{[1
]}

Vega, Francisco ^{[2
]}

Wang, Linghua ^{[3
]}

Wang, Michael L. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2021年 / 96卷 / 05期

关键词：

D O I：

10.1002/ajh.26109

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E137 / E140

页数：4

共 50 条

[1] Outcomes of Acalabrutinib Failures in Relapsed Mantle Cell Lymphoma
Jain, Preetesh
Zhang, Shaojun
Kanagal-Shamanna, Rashmi
Navsaria, Lucy
Ok, Chi Young
Tang, Guilin
Yin, C. Cameron
Badillo, Maria
Chen, Wendy
Oriabure, Onyeka
Lee, Hun Ju
Westin, Jason
Nastoupil, Loretta J.
Moghrabi, Omar
Che, Yuxuan
Samaniego, Felipe
Ahmed, Sairah
Nair, Ranjit
Li, Shaoying
Vega, Francisco
Flowers, Christopher
Wang, Linghua
Wang, Michael
[J]. BLOOD, 2020, 136
[2] Use of acalabrutinib in patients with mantle cell lymphoma
Awan, Farrukh T.
Jurczak, Wojciech
[J]. EXPERT REVIEW OF HEMATOLOGY, 2018, 11 (06) : 495 - 502
[3] REAL-WORLD TREATMENT OUTCOMES AMONG RELAPSED/REFRACTORY PATIENTS WITH MANTLE CELL LYMPHOMA TREATED WITH IBRUTINIB OR ACALABRUTINIB
Crawford, S.
Lafeuille, M. H.
Emond, B.
Harb, D.
Voladarsky, R.
Chen, N.
Karve, S.
[J]. VALUE IN HEALTH, 2023, 26 (06) : S403 - S403
[4] Acalabrutinib in mantle cell lymphoma
Kapoor, Prashant
Ansell, Stephen M.
[J]. LANCET, 2018, 391 (10121): : 633 - 634
[5] Acalabrutinib for mantle cell lymphoma
Witzig, Thomas E.
Inwards, David
[J]. BLOOD, 2019, 133 (24) : 2570 - 2574
[6] Economic Evaluation for the US of Ibrutinib Versus Acalabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma
Alrawashdh, Neda
Alkhatib, Nimer
McBride, Ali
Persky, Daniel
Abraham, Ivo
[J]. BLOOD, 2018, 132
[7] Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma
Michael Wang
Simon Rule
Pier Luigi Zinzani
Andre Goy
Olivier Casasnovas
Stephen D. Smith
Gandhi Damaj
Jeanette K. Doorduijn
Thierry Lamy
Franck Morschhauser
Carlos Panizo
Bijal Shah
Andrew Davies
Richard Eek
Jehan Dupuis
Eric Jacobsen
Arnon P. Kater
Steven Le Gouill
Lucie Oberic
Tadeusz Robak
Preetesh Jain
Melanie M. Frigault
Raquel Izumi
Dorothy Nguyen
Priti Patel
Ming Yin
Monika Długosz-Danecka
[J]. Leukemia, 2019, 33 : 2762 - 2766
[8] Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma
Wang, Michael
Rule, Simon
Zinzani, Pier Luigi
Goy, Andre
Casasnovas, Olivier
Smith, Stephen D.
Damaj, Gandhi
Doorduijn, Jeanette K.
Lamy, Thierry
Morschhauser, Franck
Panizo, Carlos
Shah, Bijal
Davies, Andrew
Eek, Richard
Dupuis, Jehan
Jacobsen, Eric
Kater, Arnon P.
Le Gouill, Steven
Oberic, Lucie
Robak, Tadeusz
Jain, Preetesh
Frigault, Melanie M.
Izumi, Raquel
Dorothy Nguyen
Patel, Priti
Yin, Ming
Dlugosz-Danecka, Monika
[J]. LEUKEMIA, 2019, 33 (11) : 2762 - 2766
[9] Economic Evaluation of Ibrutinib Versus Acalabrutinib Versus Zanubrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma
Alrawashdh, Neda
McBride, Ali
Slack, Marion
Abraham, Ivo
[J]. BLOOD, 2020, 136
[10] Acalabrutinib for adults with mantle cell lymphoma
Jurczak, Wojciech
Dlugosz-Danecka, Monika
Wang, Michael
[J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (03) : 179 - 187

← 1 2 3 4 5 →